Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV
Pablo Tebas, David Stein, Gwendolyn Binder-Scholl, Rithun Mukherjee, Troy Brady, Tessio Rebello, Laurent Humeau, Michael Kalos, Emmanouil Papasavvas, Luis J Montaner, Daniel Schullery, Farida Shaheen, Andrea L Brennan, Zhaohui Zheng, Julio Cotte, Vladimir Slepushkin, Elizabeth Veloso, Adonna Mackley, Wei-Ting Hwang, Faten Aberra, Jenny Zhan, Jean Boyer, Ronald G Collman, Frederic D Bushman, Bruce L Levine, Carl H June, Pablo Tebas, David Stein, Gwendolyn Binder-Scholl, Rithun Mukherjee, Troy Brady, Tessio Rebello, Laurent Humeau, Michael Kalos, Emmanouil Papasavvas, Luis J Montaner, Daniel Schullery, Farida Shaheen, Andrea L Brennan, Zhaohui Zheng, Julio Cotte, Vladimir Slepushkin, Elizabeth Veloso, Adonna Mackley, Wei-Ting Hwang, Faten Aberra, Jenny Zhan, Jean Boyer, Ronald G Collman, Frederic D Bushman, Bruce L Levine, Carl H June
Abstract
We report the safety and tolerability of 87 infusions of lentiviral vector–modified autologous CD4 T cells (VRX496-T; trade name, Lexgenleucel-T) in 17 HIV patients with well-controlled viremia. Antiviral effects were studied during analytic treatment interruption in a subset of 13 patients. VRX496-T was associated with a decrease in viral load set points in 6 of 8 subjects (P = .08). In addition, A → G transitions were enriched in HIV sequences after infusion, which is consistent with a model in which transduced CD4 T cells exert antisense-mediated genetic pressure on HIV during infection. Engraftment of vector-modified CD4 T cells was measured in gut-associated lymphoid tissue and was correlated with engraftment in blood. The engraftment half-life in the blood was approximately 5 weeks, with stable persistence in some patients for up to 5 years. Conditional replication of VRX496 was detected periodically through 1 year after infusion. No evidence of clonal selection of lentiviral vector–transduced T cells or integration enrichment near oncogenes was detected. This is the first demonstration that gene-modified cells can exert genetic pressure on HIV. We conclude that gene-modified T cells have the potential to decrease the fitness of HIV-1 and conditionally replicative lentiviral vectors have a promising safety profile in T cells.
Trial registration: ClinicalTrials.gov NCT00295477.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3587318/bin/zh89991302240001.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3587318/bin/zh89991302240002.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3587318/bin/zh89991302240003.jpg)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3587318/bin/zh89991302240004.jpg)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3587318/bin/zh89991302240005.jpg)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3587318/bin/zh89991302240006.jpg)
Source: PubMed